BIOLQ (Biolase) Current Deferred Revenue: $2.23 Mil (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOLQ Biolase Inc BIOLQ
16 GF Score
Price $0.00
View Full Analysis

What is Biolase Current Deferred Revenue?

Biolase BIOLQ -99.00% 16 Current Deferred Revenue is $2.23 Mil as of Sep. 2024. GuruFocus rates BIOLQ with a GF Score™ of 16/100.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Biolase's current deferred revenue for the quarter that ended in Sep. 2024 was $2.23 Mil.

Biolase Current Deferred Revenue Related Terms

Biolase Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Biolase's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biolase Current Deferred Revenue Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.24 1.91 2.26 2.11 2.45

Biolase Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.19 2.45 2.34 2.13 2.23
BIOLQ
16GF Score
Biolase Inc BIOLQ
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $2.23 Mil mean?
Biolase (BIOLQ) has a Current Deferred Revenue of $2.23 Mil as of Sep. 2024. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Biolase and its competitors.
Is Biolase's Current Deferred Revenue too high?
Biolase's current Current Deferred Revenue is $2.23 Mil. Overall, Biolase has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biolase's Current Deferred Revenue compare to OPGN and AFIB?
Biolase's Current Deferred Revenue of $2.23 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Biolase and its competitors. Biolase's current Current Deferred Revenue is $2.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biolase stock overvalued right now?
Biolase (BIOLQ) has a current Current Deferred Revenue of $2.23 Mil. The current Current Deferred Revenue is $2.23 Mil. Biolase's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Biolase (BIOLQ), the current Current Deferred Revenue is $2.23 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biolase Business Description

Address 27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
16GF Score

Get the complete analysis for BIOLQ

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price